Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Corvus Pharmaceuticals Stock Performance
NASDAQ CRVS traded up $0.10 during mid-day trading on Friday, reaching $3.62. 1,128,121 shares of the stock were exchanged, compared to its average volume of 653,862. The company has a market capitalization of $246.77 million, a P/E ratio of -3.89 and a beta of 0.67. The business's 50 day moving average is $3.66 and its 200-day moving average is $5.61. Corvus Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $10.00.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on CRVS shares. Oppenheimer restated an "outperform" rating and set a $15.00 target price (up from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.67.
Get Our Latest Stock Analysis on CRVS
About Corvus Pharmaceuticals
(
Get Free Report)
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Further Reading
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
